跳至主要内容
临床试验/NCT04579159
NCT04579159已完成不适用

Multicentre, Intern., Inv.-Initiated, Single-arm Case-finding Study of a Cloud Based Analytic Service as Screening Tool to Detect and Quantify Episodes of Absolute Arrhythmia Using an Automated, Wearable PPG-based Monitoring System

Atrial Fibrillation Network7 个研究点 分布在 3 个国家目标入组 882 人开始时间: 2021年1月26日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
882
试验地点
7
主要终点
Proportion of participants with newly detected AA within 4 weeks of device use of all participants included in the study

研究概览

简要总结

This feasibility study will develop and evaluate pathways to identify participants with wearable-detected absoulute Arrhythmia (AA) and to enable local study teams to contact them regarding participation in a controlled trial of oral anticoagulation in this population, which will be conducted after the feasibility study.

详细描述

In this study, the feasibility of evaluating the efficacy of a cloud based analytic service in combination with a PPG-wearable in detecting AA will be assessed and the number of cases found. The design aims to provide simple, low-threshold access to this screening technology targeting at-risk populations. This study will not cause any restrictions on the usual care of the study participants. Access to the screening will be provided close to home and free of charge. The app will also be used to validate and enhance the clinical information about the participants captured during the study. This information will be used to define and refine target groups with highest screening efficiency and, in the long-term, outcome benefits. The study will describe the prevalence of AA in an unselected population that can be reached by a low-threshold screening procedure. The study will also generate important information on the different possible screening environments in different countries (e.g. pharmacies, GP practices, etc). Structures of work-up and continuous patient management in screen-positive individuals will be described and may help to design screening pathways in the main trial. By verifying the wearable-diagnoses by ECG in all screen-positive and a random selection of screen-negative participants, the diagnostic accuracy of the wearable in combination of cloud based analytic service can be estimated. Cost effectiveness assessment will evaluate the cost of low-threshold remote screening per patient identified and help guide to target high risk groups with optimal screening yield in the future. The collected data will provide the sound basis for the design and conduct of a large outcome trial.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Screening
盲法
None

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion criteria:
  • 65 years or older
  • Willing and able to provide informed consent
  • Owning mobile phone compatible with the PPG-wearable

排除标准

  • Known current or planned oral anticoagulation treatment

结局指标

主要结局

Proportion of participants with newly detected AA within 4 weeks of device use of all participants included in the study

时间窗: Screening per participant: 4-8 weeks

Proportion of participants with newly detected AA within 4 weeks of device use of all participants included in the study

次要结局

  • Differences by rout fo invitation and enrolment(Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months)
  • Follow-up EQ-5DL-5L viscual analogue scale of participants with positve PPG(Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months)
  • Propotion of participants with AA detected at any time, including those with AA detected within the full time of recording(Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months)
  • Time from completed enrolment to the first positive screening, taking death as compeeting risk into account(Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months)
  • Duration of atrial arrhythmia episodes(Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months)
  • Compliance: The compliance of participants with protocol with regards to the measurement procedure of the app and wearable(Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months)
  • Regional differences of AA prevalance (diagnostic yield)(Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months)
  • Detection of AF: Number of participants with clinically confirmed arrhythmias during Holter ECG(Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months)

研究者

发起方
Atrial Fibrillation Network
申办方类型
Other
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验